INT122481
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
In contrast, low uPA mRNA expression was not significantly associated with longer metastasis-free survival (p = 0.41) (Figure 4). | |||||||||||||||
| |||||||||||||||
|
Nevertheless, in metastatic breast cancer, retrospective studies showed that elevated uPA or PAI-1 present in the primary tumor are associated with a poor response to later palliative endocrine therapy [14] suggesting that high levels of uPA and/or PAI-1 do reflect an aggressive phenotype that may be overcome by early systemic therapy in the adjuvant setting but not by palliative therapy at a later stage of the disease. | |||||||||||||||
| |||||||||||||||
|
Several international research groups have demonstrated that the protein content of uPA and PAI-1 in the tumor correlates with disease aggressiveness and has a strong prognostic impact on disease-free survival and overall survival in patients with primary breast cancer [1-6]. | |||||||||||||||
| |||||||||||||||
|
UPA EC has been shown to be associated with a lower pregnancy rate compared to LNG EC. | |||||||||||||||
| |||||||||||||||
|
Pre-clinical studies indicate that UPA binds to human progesterone, glucocorticoid and androgen receptors at approximately 6, 1.5 and 0.2 times the affinity of the endogenous ligands and shows in vivo anti-glucocorticoid and anti-androgen activity at doses approximately 50-fold greater than those needed for anti-progestin effect. | |||||||||||||||
| |||||||||||||||
|
The databases from the two randomized controlled trials comparing UPA with LNG EC (n = 1549 women treated <72 hours after unprotected intercourse plus 1899 women treated <120 hours) were merged in a meta-analysis including the primary efficacy populations defined in each study.47 Comparisons were done for different time windows of treatment in relation to unprotected intercourse. | |||||||||||||||
| |||||||||||||||
|
It has recently been demonstrated that binding of u-PA to its receptor increases pro-MMP-2,-9 [23] and -13 [16] activation, and that in the absence of cells, plasmin not only fails to activate pro-MMPs, but rapidly degrades them [23]. | |||||||||||||||
| |||||||||||||||
|
Since UPA binds the progesterone receptor with high affinity, it may interfere with the action of progestogen-containing drugs. | |||||||||||||||
| |||||||||||||||
|
In combination with other ECM proteins found in our analysis, PAI-1 and uPA, the association with DFI and OS became even more significant (p < 0.001). | |||||||||||||||
| |||||||||||||||
|
PAI-1 and PAI-2 belong to the serine protease inhibitor super-family and are involved in the regulation and inhibition of binding between uPA and its receptor. | |||||||||||||||
| |||||||||||||||
|
Moreover, interaction between uPA and COX-2 was also shown in some cancer cells [35,36] and in corneal injury and inflammation [37]. | |||||||||||||||
| |||||||||||||||
|
Domain 1 is the only domain involved in (pro)-u-PA binding, domain 3 also participates in providing the u-PA binding site. | |||||||||||||||
| |||||||||||||||
|
The receptor (u-PAR/CD87) focuses the enzymatic activity of u-PA and allows activation of plasminogen (PG) at the cell surface, which in turn, is bound to the cell membrane by ? | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.